First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan

On May 29, 2017 Takara Bio Inc. (Takara Bio), reported that the first patient with melanoma has been enrolled into Oncolytic Virus HF10(TBI-1401) phase II clinical trial in Japan on May 26, 2017 (Press release, Takara Bio, MAY 29, 2017, View Source [SID1234519312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!



In this clinical study, HF10 is administered in combination with Ipilimumab in patients with unresectable or metastatic melanoma, and its efficacy and safety will be evaluated as well as immunological test. Also, the HF10 manufactured at Center for Gene and Cell, Takara Bio’s facility, is used in this study.

Takara Bio attempts to achieve the accelerated approval utilizing the conditional and term-limited approval system for regenerative medicine under "The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical devices". Takara Bio aims to commercialize the HF10 cancer therapy in the fiscal year 2018 in Japan.